↓ Skip to main content

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient

Overview of attention for article published in Journal for Immunotherapy of Cancer, September 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (65th percentile)

Mentioned by

twitter
6 tweeters

Citations

dimensions_citation
26 Dimensions

Readers on

mendeley
30 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
Published in
Journal for Immunotherapy of Cancer, September 2015
DOI 10.1186/s40425-015-0084-y
Pubmed ID
Authors

Nu T. Lu, Jeffrey Raizer, Erwin P. Gabor, Natalie M. Liu, James Q. Vu, Dennis J. Slamon, John L. Barstis

Abstract

We describe the clinical and therapeutic course of a 51-year-old woman with HER-2+ breast cancer who developed leptomeningeal (LM) and spinal cord metastases after 8 years of stable disease on combination therapy with intravenous (IV) trastuzumab. Due to progressive CNS disease, intrathecal (IT) trastuzumab was introduced to enhance HER-2+ therapy into the CSF space. A combination HER-2+ targeted approach achieved clinical remission with stable disease in our patient 46 months after she was diagnosed with LM metastases. However, spinal cord C-1 metastasis was not fully controlled with IT trastuzumab, ultimately leading to the patient's respiratory compromise. In our patient, IT trastuzumab immunotherapy improved prognosis and was an effective strategy to manage HER-2+ LM disease. Given alone or alongside other anti-HER-2+ therapeutics with sufficient CNS penetration, IT trastuzumab could extend the lifespan of patients with leptomeningeal and CNS metastases.

Twitter Demographics

The data shown below were collected from the profiles of 6 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Egypt 1 3%
Unknown 29 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 7 23%
Other 3 10%
Researcher 3 10%
Student > Postgraduate 3 10%
Student > Doctoral Student 2 7%
Other 7 23%
Unknown 5 17%
Readers by discipline Count As %
Medicine and Dentistry 11 37%
Pharmacology, Toxicology and Pharmaceutical Science 3 10%
Psychology 3 10%
Neuroscience 2 7%
Agricultural and Biological Sciences 2 7%
Other 4 13%
Unknown 5 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 16 October 2015.
All research outputs
#6,840,164
of 13,591,964 outputs
Outputs from Journal for Immunotherapy of Cancer
#545
of 823 outputs
Outputs of similar age
#83,626
of 246,678 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#1
of 1 outputs
Altmetric has tracked 13,591,964 research outputs across all sources so far. This one is in the 49th percentile – i.e., 49% of other outputs scored the same or lower than it.
So far Altmetric has tracked 823 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 17.5. This one is in the 33rd percentile – i.e., 33% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 246,678 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 65% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them